Select Medical Shares Down 20% Despite Q2 Earnings Beat

Select Medical Holdings Corporation (SEM) shares declined over 20% following its Q2 2025 earnings report, despite beating adjusted EPS ($0.32 vs. $0.28 estimate) and revenue ($1.3B, up 4.5% Y/Y) consensus estimates. The significant stock drop appears driven by a miss on overall Adjusted EBITDA ($125.4M vs. $129M estimate) due to rising service costs, a 21.6% year-over-year EBITDA decline in the Critical Illness Recovery Hospital segment, and deteriorating occupancy rates in the Rehabilitation Hospital segment, signaling investor apprehension over profitability and operational efficiency despite the company reaffirming its full-year 2025 outlook.

Analysis

Select Medical Holdings (SEM) experienced a significant 20.4% share price decline despite reporting Q2 2025 results that surpassed consensus estimates for both adjusted EPS ($0.32 vs. $0.28) and revenue ($1.3 billion, a 4.5% year-over-year increase). The market's negative reaction appears driven by deteriorating profitability and operational pressures beneath the headline figures. Specifically, adjusted EBITDA of $125.4 million missed estimates, while total costs rose 3.9% year-over-year. Segment performance was mixed and revealed underlying weaknesses: the largest segment, Critical Illness Recovery Hospital, saw its revenue decline by 0.6% and its adjusted EBITDA plummet 21.6% with a 250 bps margin contraction. Conversely, the Rehabilitation Hospital segment posted strong 17.2% revenue growth, but this was undercut by a 200 bps drop in its occupancy rate and a 50 bps decline in its EBITDA margin. Furthermore, net cash from operations fell sharply to $110.3 million from $278.2 million a year ago. This contrast between the severe market sell-off and management's decision to reaffirm its full-year 2025 guidance presents a key divergence, questioning whether the market is overreacting or if the company's outlook is optimistic given the evident margin pressures.

Key Decisions for Investors

• Investors should critically assess the credibility of the reaffirmed full-year 2025 guidance, particularly the adjusted EBITDA target, given the significant Q2 margin erosion and rising service costs.
• Monitor the performance of the Critical Illness Recovery Hospital segment in upcoming quarters, as its 21.6% year-over-year EBITDA decline was a primary driver of weakness and its recovery is crucial for a turnaround.
• Following the 20.4% price drop, weigh the more attractive valuation against clear operational headwinds, including declining occupancy rates in the Rehabilitation Hospital segment and a significant drop in cash from operations.
• Consider the company's capital allocation, as the ongoing share repurchases and dividends signal management confidence but must be evaluated against the backdrop of rising debt and weakening operational cash flow.